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Abstract 
Aerosol vaccination via the mucosa targets an epithelium critical to host defence against inhaled pathogens, 
potentially avoids needle injection, and provides an exciting opportunity in the development of stable dry powder 
vaccine formulations. Specialised cells in the mucosa are able to take up and guide antigens directly to immune cells. 
In contrast to soluble antigen formulations, particles with antigen also provoke a local sIgA mediated immune 
response before being presented to the systemic immune system. In this study, particles containing the model antigen 
BSA and chitosan as stabiliser with adjuvant activity are produced by spray drying. The compatibility and uptake of 
these particles via the respiratory epithelium is determined in vitro on Calu-3 cells. The in vitro deposition studies are 
performed in a nasal cast made from CT scan data using a novel nasal dry powder device. The deposition profile is 
optimised by the use of interactive mixtures with a low separation capacity. The spray drying process results in 
spherical particles with a size in the low micrometer range (x50 3 µm), which are well tolerated when administered to 
the cells and which are readily taken up. As the particles have to be big enough to be retained in the appropriate place 
in the respiratory tract (e.g. the nasal cavity) to be taken up efficiently, the primary particles are too small. Deposition 
studies show a high fraction of almost 56% transiting the nose and being capable of inhalation. This fraction can be 
reduced by utilising an interactive mixture with a carrier, where only 5% of the antigen carrying particles leave the 
nasal cavity. Particulate vaccine formulations are a promising formulation approach for mucosal vaccination targeting 
the nasal mucosa. With small antigen carrying particles immobilised on carrier particles, the antigen is delivered 
exclusively to the nose. 
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1. Introduction 
Conventional vaccines are administered by parenteral, mostly intramuscular application of a solution or 
a suspension containing the virus preparation as dead or attenuated whole virus, split virus preparation or 
purified antigen [1] and often further substances acting as adjuvants like alum in adsorbate vaccines or oil-
in-water-emulsions containing squalene and other excipients [2]. These vaccine preparations result in a 
good systemic immune response [3]. Nonetheless, one of the most famous vaccines, the Sabin polio 
vaccine [4] is an oral vaccine utilising the mucosal route for vaccination. Other examples are oral typhus 
and cholera vaccines. Mucosal vaccination utilises a tissue naturally being involved in immune defence as 
it is the first contact barrier to overcome by pathogens often entering the body via the respiratory or the 
gastro-intestinal tract [5]. Hence the mucosal tissues of the human body are well equipped with immune 
competent cells being prepared for uptake of particulate agents like pathogens and almost 80% of all 
immune cells in the body are associated with the mucosal immune system [6]. The structures being 
responsible for an immune response are called “mucosal associated lymphoid tissue” (MALT) and can be 
divided according to their localisation in e.g. nasal associated lymphoid tissue (NALT), bronchial 
associated lymphoid tissue (BALT) and further lymphoid structures [7]. Above the usual immune 
response, activating the mucosal immune system by particulate systems leads to a local immune reaction 
resulting in secretion of IgA (sIgA dimers) being present on the apical side of the mucosal barrier in the 
mucus layer. With this, pathogens may be recognised in the moment they enter the body resulting in a 
very effective and protective immune defence [8]. Additionally, the mucosal tissues within the body are 
connected (called the “common mucosal immune system” [9]) and with this, vaccination via a certain 
mucosal tissue also results in an sIgA response in distant tissues. Whereas it is rather complex to 
formulate antigens, i.e. proteins, peptides or lipopolysaccharide structures, for oral delivery due to the 
hostile conditions in the gastro-intestinal tract, administering antigens for vaccination to the NALT or 
BALT offers a promising alternative to parenteral vaccination [10]. With this, needle injection can be 
avoided as such a vaccine may be administered via inhalation [11] or a nasal spray [12] and hence trained 
medical personnel are not needed for vaccination. Further, the risk of needle-spread infections is 
eliminated. In terms of vaccine formulation, it is not limited to a liquid, injectable preparation often 
having poor storage stability [13] and hence, vaccine formulations as dry powder with increased storage 
and transport stability for particulate uptake via the upper respiratory mucosa after nasal administration 
offer a promising strategy in modern vaccination.  
In this study, bovine serum albumin (BSA) as model protein antigen is formulated as small non-soluble 
particles capable for particulate uptake and this formulation is further processed to a dry powder for nasal 
administration. 
2. Materials and Methods 
2.1. Primary particles  
The primary particles have been produced by spray drying a solution of BSA (Sigma, St. Louis, MO, 
USA) and chitosan (Chitoclear, Primex, Iceland) using a B290 lab spray dryer (Büchi, Flawil, 
Switzerland). The dry product has been stored at room temperature in a desiccator until further use. The 
particle size has been analysed by laser diffraction using a Helos system (Sympatec, Clausthal-Zellerfeld, 
Germany) with dry dispersion at 3 bar. Particle morphology has been evalutated by scanning electron 
microscopy (DSM 940, Zeiss, Oberkochen, Germany). 
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2.2. Interactive mixtures 
The interactive mixtures have been produced by blending different w/w fractions (2%, 5% and 10%) 
of primary chitosan-BSA particles with a spray dried mannitol quality (Pearlitol 200 SD, Roquette, 
Lestrem, France) in a particle size between 45 and 90 µm (sieve fraction). Mannitol as carrier and the 
primary particles were sandwich-weighed in a small container and were blended for 15 min in a Turbula 
mixer (W.A. Bachofen, Switzerland). After blending, the mixtures were sieved and blend conformity was 
assured to be below 5% rsd by a protein assay (Micro-BCA assay kit, Thermo Scientific, Rockford, IL, 
USA), otherwise the blending process was repeated. 
2.3. Aerodynamic assessment 
Aerodynamic assessment of the formulations intended for nasal administration was performed in a 
nasal cast model (Boehringer Ingelheim, Ingelheim, Germany). This cast model is made from a CT scan 
of a human adults nose and can be divided into five sections representing the nostrils, nasal vestibule, 
lower turbinates, middle and upper turbinates and nasopharynx (Fig. 1 a+b). The post-nasal fraction can 
either be collected in a cup if the model is operated without simulated inspiration airflow or a filter is 
connected to the nasopharynx section if operated at a normal nasal breathing of 15 L/min. The cast was 
coated prior to deposition studies to mimic the mucus layer and minimise particle bounce [14]. The 
formulations were administered to the cast with the PowderJet (Fig. 1 c), a novel nasal dry powder 
reservoir device from RPC Formatec (Mellrichstadt, Germany). After administration, the cast was 
disassembled and all parts were washed carefully to collect the deposited fractions. Protein content was 
determined and the deposition profile is shown as % deposition of recovery (n=3) in the different sections 
of the cast model.  
Fig. 1. (a) nasal cast model; (b) close up of the different sections of the cast; (c) powder cloud evolving from PowderJet device
2.4. Stability 
Stability of the incorporated model antigen BSA has been confirmed by gel electrophoresis (SDS-
PAGE). Samples of freshly produced primary particles and particles being stored at different conditions 
were dissolved, mixed with loading buffer and applied to a 10% polyacrylamide gel. Electrophoresis was 
performed at 200 V for 55 min, pure BSA and mannitol were used as control samples. A MW ladder 
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(SeeBlue Plus 2 Prestained Standard, invitrogen, Darmstadt, Germany) served as reference. After 
electrophoresis the gel was stained and photographed.  
2.5. Uptake and tolerability 
For uptake and tolerability experiments, a cell culture of respiratory epithelial cells (Calu-3 from 
ATCC, Manassas, VA, USA) was utilised. The Calu-3 cells were cultivated in 12-well-Transwell plates 
(greiner bio-one, Frickenhausen, Germany) at a cell number of 4x105 cells per well. Formation and 
integrity of the monolayer is followed by TEER (transepithelial electrical resistance) measurements 
(EVOM, WPI, Sarasota, FL, USA). For tolerability testing, different amounts of chitosan-BSA particles 
were dispersed on the cellular surface of the monolayer (n=3) and were incubated for four hours. 
Afterwards the particles were removed by gentle washing with HBSS and an MTT solution was incubated 
with the cells for two hours. In living cells the yellow dye is reduced to a blue formazan indicating 
cellular viability [15]. The cells were lysed and detection and quantification of the formazan crystals were 
performed by a multiwell plate reader (Thermo Spectra III Reader with software easyWINfitting, V6.0a, 
Tecan, Austria) at 570 nm (reference wavelength 690 nm). Cells incubated with HBSS served as negative 
control (100% viability) and SDS was the positive control (0% viability). From the data, the LC50
concentration was calculated as the amount where 50% of the cells survived. For uptake experiments, 
chitosan particles with carboxyfluorescein instead of BSA have been produced. The particles were 
administered to the apical surface of the monolayer and samples of the basolateral medium were collected 
over time and analysed due to carboxyfluorescein content while monolayer integrity was followed by 
TEER measurements. After four hours, the cellular layer was prepared for fluorescence microscopy and 
particle localisation was performed utilising a Leica fluorescence microscope (Leica, Wetzlar, Germany). 
Fig. 2. (a) SEM picture of spray-dried chitosan-BSA particles (5000x magnification); (b) SDS-PAGE of different formulations (M is
MW ladder ,BSA is pure BSA, form 1+2 after spray-drying, form 4 after storage at RT, 40/75 after storage at stress conditions) 
3. Results and Discussion 
The primary particle production by spray drying resulted in spherical particles of about 3 µm in 
diameter as determined by laser diffraction and SEM (Fig. 2a). The BSA content in the product was 
between 15% (w/w) and 20% (w/w) depending on the concentration of the solution. Chitosan is a 
polysaccharide made from chitin from crab shells by deacetylation and is a partially water insoluble 
polymer bearing amino groups and with this having a positive charge. It was added to the spray drying 
process as particle forming agent to stabilise the protein during drying. Further, chitosan is known to have 
adjuvant activity and may facilitate epithelial uptake [16]. Although the formulation process comprises 
thermal drying in a spray dryer, BSA as model protein antigen stays intact during formulation as shown 
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with SDS-PAGE (Fig. 2b, form 1+2) and also during storage at room temperature for 3 months (Fig. 2b, 
form 4). If stored at elevated temperature and humidity (40°C, 75% rH), BSA is degraded (Fig. 2b, 
40/75). Whereas pure BSA does not affect cellular viability, chitosan-BSA particles may reduce cellular 
viability after an incubation of 4 hours depending on the concentration resulting in a LC50 value of 
0.39 mg/cm². Chitosan-BSA particles also reversibly reduce TEER of a Calu-3 monolayer in culture. As 
chitosan is said to open tight junctions, the reduction of transepithelial resistance during chitosan contact 
can be explained by this effect. Other studies indicate that chitosan may be regarded as safe excipient 
without any toxic effects in vivo [17]. The uptake experiment with chitosan-carboxyfluorescein particles 
showed that carboxyfluorescein as marker substance is released into the basolateral acceptor medium 
indicating transepithelial transport (Fig. 3). As this might also be due to a release of the marker substance 
prior to transport, fluorescence microscopy was used to localise the fluorescent particles after 4 hours of 
incubation. Apart from diffuse background fluorescence due to dissolved carboxyfluorescein, distinct 
particles could be localised within the cells indicating uptake and transport (Fig. 3, inserted picture). 
Fig. 3. Transepithelial transport of carboxyfluorescein via a Calu-3 monolayer over time, n=2, error bars represent min-max; insert: 
fluorescence micrograph (1000x magnification) of particles in the cells after 4 hours incubation (at white arrows) 
The administration via the nose was chosen as it is the easiest accessible part of the respiratory system 
and a patient may operate a nasal spray without problems. Additionally, the nasal associated lymphoid 
tissue is well developed in all patients, whereas development of BALT may differ from patient to patient 
according to his medical history [7]. Although the NALT is concentrated within the Waldeyers ring in the 
nasopharynx, it could be shown that there are antigen sampling cells distributed throughout the whole 
nose, so a formulation should cover the whole inner nasal surface in order to increase efficiency. With a 
size of below 3 µm the primary chitosan-BSA particles are rather in the size range for inhalable 
formulations than for nasal formulations, where the particles should be well above 10 µm to be kept in the 
nose. So, it is not surprising to see a high post-nasal fraction of more that 55% when analysing the 
aerodynamic behavior and deposition profile after administration to the nasal cast model operated at 
15 L/min (Fig. 4a). The post-nasal fraction will potentially get inhaled to the deep lung, which should be 
avoided when formulating a nasal product, although a certain deposition in the upper bronchial airways 
might enhance the efficiency of a respiratory vaccine product as it would also target the BALT, if present. 
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For increasing the nasal fraction, the small particles need to behave like bigger particles in order to be 
deposited in the nose. To facilitate this, interactive mixtures with a low separation tendency were 
introduced. With this, the small particles should adhere to a larger carrier during administration and 
deposit together with the carrier. Once deposited, the small particulate antigen can be separated following 
dissolution of the carrier and may be taken up. 
Fig. 4. (a) deposition profile of pure chitosan-BSA particles and blends with mannitol and 2%, 5% and 1% primary particles in a
nasal cast operated at 15 L/min, n=3, error bars represent min-max; (b) SEM picture of blend with10% chitosan-BSA particles on 
mannitol (500x magnification) 
Mannitol was chosen as carrier for the interactive mixtures as it is water soluble, does not exhibit any 
reducing activity influencing protein stability and it is not hygroscopic with this assuring a dry powder 
formulation over storage time. The used quality is a granulated quality resulting in a very rough surface 
where the small primary particles may well adhere to and stay on the carrier during application (Fig. 4b). 
Other mannitol qualities like crystalline mannitol have been tested as well, but the small particles rather 
separate from the carrier and show a very varying deposition profile. The deposition profile after 
administration of the three different carrier blends all showed a significantly decreased post-nasal fraction 
between 5% and 7% indicating a good co-deposition of carrier and small particles (Fig. 4a). It could be 
observed that increasing amounts of chitosan-BSA particles result in an increase of post-nasal fraction 
and higher variability demonstrating that the additional particles are not as good adhered to the carrier as 
the lower amount. Apart from a higher nasal deposition, the carrier blends also show a better 
dispersibility with the PowderJet.  
Formulation optimisation will comprise the use of adhesives to fix the small particles more efficiently 
to the carrier. Further on, other polymers apart from chitosan will be tested for primary particle formation 
in order to optimise cellular uptake and antigen release. Finally, the concept will be transferred to other 
antigens to prove antigenicity in an in vivo model. 
4. Conclusion 
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Particulate dry powder vaccine formulations are a promising formulation approach for mucosal 
vaccination targeting the nasal mucosa. A model protein antigen can be formulated as dry powder by 
spray drying. The formulation is stable and can be taken up by respiratory epithelial cells. With the small 
antigen carrying particles being immobilised on carrier particles, the antigen can be delivered exclusively 
to the nose. 
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